These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37596977)

  • 1. What impacts the acceptability of wearable devices that detect opioid overdose in people who use opioids? A qualitative study.
    Tas B; Walker H; Lawn W; Matcham F; Traykova EV; Evans RAS; Strang J
    Drug Alcohol Rev; 2024 Jan; 43(1):213-225. PubMed ID: 37596977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acceptability of overdose alert and response technologies: introducing the TPOM-ODART framework.
    Dumbrell J; Daneshvar H; Oteo A; Baldacchino A; Matheson C
    Harm Reduct J; 2023 Mar; 20(1):40. PubMed ID: 36967388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to use a wearable device capable of detecting and reversing overdose among people who use opioids in Philadelphia.
    Kanter K; Gallagher R; Eweje F; Lee A; Gordon D; Landy S; Gasior J; Soto-Calderon H; Cronholm PF; Cocchiaro B; Weimer J; Roth A; Lankenau S; Brenner J
    Harm Reduct J; 2021 Jul; 18(1):75. PubMed ID: 34301246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I don't go to funerals anymore": how people who use opioids grieve drug-related death in the US overdose epidemic.
    Schlosser AV; Hoffer LD
    Harm Reduct J; 2022 Oct; 19(1):110. PubMed ID: 36183109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
    Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
    Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder.
    Jones JD; Campbell AN; Brandt L; Metz VE; Martinez S; Wall M; Corbeil T; Andrews H; Castillo F; Neale J; Strang J; Ross S; Comer SD
    Drug Alcohol Depend; 2022 Aug; 237():109505. PubMed ID: 35709575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in overdose experiences and prevention behaviors among people who use opioids in Baltimore, MD, 2017-2019.
    Dayton L; Mazhnaya A; Schneider KE; Kong X; Winiker A; Davey-Rothwell M; Tobin KE; Latkin CA
    Drug Alcohol Depend; 2021 Apr; 221():108650. PubMed ID: 33684772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality risk and causes of death among people who use opioids in a take-home naloxone cohort.
    Ericson ØB; Eide D; Lobmaier P; Clausen T
    Drug Alcohol Depend; 2024 Feb; 255():111087. PubMed ID: 38228056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
    Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB
    Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff.
    Binswanger IA; Koester S; Mueller SR; Gardner EM; Goddard K; Glanz JM
    J Gen Intern Med; 2015 Dec; 30(12):1837-44. PubMed ID: 26055224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of opioid overdose: current approaches and recent advances.
    Britch SC; Walsh SL
    Psychopharmacology (Berl); 2022 Jul; 239(7):2063-2081. PubMed ID: 35385972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.